April 9, 2025
Valneva and LimmaTech vaccinate first participants in phase 2 infant study of tetravalent shigella vaccine candidate S4V2
Valneva SE, a specialty vaccine company, and LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases,…